The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...
An expert discusses how health plans evaluate high-cost NMIBC therapies by examining total cost of care, weighing risk versus reward for treatments like gene therapy that can cost over a million ...
CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Results remained consistent across multiple sensitivity analyses and scenarios (different age populations, various assumptions), confirming the model’s reliability. Mark H. Meissner M.D., surgeon at ...
Background Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients commonly results in vascular calcification leading to increased risk of cardiovascular disease. Phosphate binders ...
A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...
DUBLIN--(BUSINESS WIRE)--The "Inhalation and Nasal Spray Generic Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Inhalation and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback